#HVO hVIVO PLC – £16.8m RSV contract & Trading ahead of guidance December 13, 2023 – Posted in: Blog, hVIVO (HVO)

£16.8m full-service RSV contract with top five global pharma client Highlights · Pharma client is funding expedited manufacture of additional supply of RSV challenge agent · Confirmatory challenge cohort to verify infectivity of the new RSV challenge virus batch · Multiple cohort challenge trial to test efficacy of client’s RSV antiviral candidate · Trading ahead of previous market expectations driven by margin expansion hVIVO plc (AIM & Euronext: HVO), the world leader in testing…

#ORPH Open Orphan plc – Positive in vitro results for FLU-v published September 30, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that positive data from a peer-reviewed study evaluating the in vitro efficacy of FLU-v, Imutex Limited’s (“Imutex”) broad spectrum influenza vaccine, has been published in the scientific journal Vaccines.1 Previous clinical studies have demonstrated that FLU-v induced increased…

#HVO hVIVO PLC – £16.8m RSV contract & Trading ahead of guidance December 13, 2023 – Posted in: Blog, hVIVO (HVO)

#ORPH Open Orphan plc – Positive in vitro results for FLU-v published September 30, 2022 – Posted in: Blog, Open Orphan (ORPH)

Address

Contact

Social

LEGAL